Legend Biotech prices IPO above the range at $23

Legend Biotech, a clinical stage CAR-T immuno-oncology biotech being spun out of GenScript, raised $424 million by offering 18.4 million ADSs at $23, above the range of $18 to $20. Legend Biotech plans to list on the Nasdaq under the symbol LEGN. Morgan Stanley, J.P. Morgan and Jefferies acted as lead managers on the deal.

The article Legend Biotech prices IPO above the range at $23 originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.